Brain Fog and Long Covid
Brain Fog and Long Covid Dr Steve Allder, Consultant Neurologist at Re:Cognition Health: It is unknown who is most affected by cognitive complaints induced by Covid-19 […]
Brain Fog and Long Covid
Brain Fog and Long Covid Dr Steve Allder, Consultant Neurologist at Re:Cognition Health: It is unknown who is most affected by cognitive complaints induced by Covid-19 […]
Long Covid Metro blog
Long Covid Metro blog Brain Fog & Long Covid Consultant Neurologist Dr Steve Allder shares his insight with the Metro: Dr Steve Allder was recently […]
Turning Point for Brain Injury in Contact Sport
Re:Cognition Health is delighted to read the recommendations and insights published on 22 July 2021 by the Department for Digital, Media, Culture and Sport, the Drake […]
Biogen FDA Accelerated Approval Under Investigation
By Rigby Sampson On Friday 9th July, Janet Woodcock the Acting Commissioner of the FDA (and former Director of the Centre for Drug Evaluation and Research […]
Minimum
Pollution and the brain Re:Cognition Health applaud new Fintech start up Minimum.eco dedicated to making carbon neutrality easily accessible to all businesses. Minimum enables businesses to calculate and offset the carbon footprint of its […]
Proactive Measures To Protect Against Dementia
Dr Emer MacSweeney was featured in the Daily Mail, exploring some of the proactive measures we can take to help protect against dementia. At Re:Cognition Health, we […]
The negative effects of working long hours
The negative effects of working long hours According to a recent global study, 745,000 people died in the past 12 months, from heart disease or stroke […]
IS ADHD Over-Diagnosed in Children and Adolescents?
IS ADHD Over-Diagnosed in Children and Adolescents? A recent study published in JAMA (Journal of the American Medical Association) Network has revealed that Attention Deficit Hyperactivity […]
Aducanumab, what this means for the UK
Aducanumab, what this means for the UK On Monday 7th June 2021 the USA approved the first medication, ever, to combat the underlying cause of Alzheimer’s Disease. Aducanumab, […]
Aducanumab receives FDA Approval
First Alzheimer’s treatment to slow disease progression receives FDA approval on 07 June 2021 Aducanumab, the first disease modifying treatment for Alzheimer’s disease, which was tested […]
Sign Up for Our Newsletter
Get our latest news, insights, and expert knowledge
"*" indicates required fields